eti-cel — Full data
Q4 2026
Cellectis expects to present the full Phase 1 dataset in Q4 2026.Source filing
CLLS biotech catalysts & pipeline
CELLECTIS SA · Data as of 2026-10-25
Upcoming catalysts
lasme-cel — Interim data
Q4 2026
The first interim analysis for the pivotal Phase 2 of the BALLI-01 trial is expected in Q4 2026.Source filing
cema-cel — Interim data
mid-2027
Allogene announced that study accrual is anticipated to be complete by the end of 2027 and that it anticipates an interim Event-Free Survival (EFS) analysis in mid-2027 and the primary EFS analysis in mid-2028.Source filing
.HEAL-101 — Initial data
H2 2027
Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelySource filing
.HEAL-201 — Initial data
H1 2028
Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelySource filing
lasme-cel — NDA/BLA submission
2028
BLA submission anticipated in 2028Source filing
cema-cel — Clinical data readout
mid-2028
Allogene announced that study accrual is anticipated to be complete by the end of 2027 and that it anticipates an interim Event-Free Survival (EFS) analysis in mid-2027 and the primary EFS analysis in mid-2028.Source filing